iBio Reports Fiscal Third Quarter 2025 Financial Results

Core Viewpoint - iBio, Inc. reported significant progress in its financial position and pipeline development during the third quarter of fiscal 2025, including a successful equity raise and promising data for its lead therapeutic candidates [2][4]. Financial Results - For the third quarter ended March 31, 2025, iBio reported R&D expenses of approximately $1.9 million, an increase of about $1.0 million compared to $0.9 million in the same period of 2024, primarily due to higher spending on consultants, supplies, and personnel [7]. - General and administrative (G&A) expenses for the same period were approximately $3.0 million, up from $2.7 million in 2024, with the increase attributed to IT costs, consulting fees, and franchise taxes [7]. - The net loss from continuing operations for the third quarter was approximately $4.9 million, or $0.49 per share, compared to a net loss of approximately $2.6 million, or $0.71 per share, in the same period of fiscal 2024 [7]. - As of March 31, 2025, cash, cash equivalents, and restricted cash totaled approximately $5.2 million, which increased to approximately $10.5 million following a warrant inducement transaction in April 2025 [7]. Corporate Updates - iBio successfully transitioned to trading on the Nasdaq Stock Exchange under the ticker symbol "IBIO," enhancing visibility and liquidity, and aligning with its strategy to attract long-term institutional investors [7]. - The company reported promising non-human primate data for IBIO-600, a long-acting anti-myostatin antibody, indicating extended half-life and dose-dependent muscle growth [7]. - iBio in-licensed a first-in-class Activin E antibody from AstralBio, expanding its pipeline focused on cardiometabolic diseases and obesity [7]. - The company raised $6.2 million in gross proceeds through a warrant inducement transaction, strengthening its balance sheet and providing additional working capital for pipeline advancements [7].